Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases

Canadian Journal of Gastroenterology

Volumn 26, Issue 3, 2012, Pages 125-129

  Himoto, Takashi ^a   Yoneyama, Hirohito ^a   Kurokohchi, Kazutaka ^a   Inukai, Michio ^a   Masugata, Hisashi ^a   Goda, Fuminori ^a   Haba, Reiji ^a   Watanabe, Seishiro ^b   Senda, Shoichi ^a   Masaki, Tsutomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Antibodies to ds DNA; Antibodies to p53; Autoimmune hepatitis; Primary biliary cirrhosis

Indexed keywords

ANTIBODY P53; AUTOANTIBODY; AZATHIOPRINE; CASPASE 3; CORTICOSTEROID; DOUBLE STRANDED DNA; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIVER DISEASE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE;

EID: 84858191790     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/890698     Document Type: Article

References (30)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutation in human cancers. Science 1991;253:49-53
2. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from colon carcinomas cooperate with rats in transforming primary rat cells: A comparison of the "hot spots" mutant phenotypes. Cell Growth Differ 1990;1:571-80.
3. Soussi T. p53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res 2000;60:1777-88. (Pubitemid 30207629)
4. Craford LV, Pim DC, Bulbrook RD. Detection of antibodies against cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8 (Pubitemid 12003724)
5. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994;69:809-16. (Pubitemid 24140657)
6. Volkmann M, Müller M, Hofmann WJ, et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the a-fetoprotein status. Hepatology 1993;18:559-65. (Pubitemid 23259954)
7. Himoto T, Kuriyama S, Zhang JY, Chan EKL, Nishioka M, Tan EM. Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. Int J Oncol 2005;26:311-7.
8. Himoto T, Kuriyama S, Zhang JY, et al. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol 2005;27:1079-85.
9. Shiota G, Kishimoto Y, Suyama A, et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol 1997;27:661-8. (Pubitemid 27448750)
10. Kovacs B, Patel A, Hershey JN, Dennis GJ, Kirschfink M. Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arth Rheum 1997;40;980-5.
11. Mariette X, Sibilia J, Delaforge C, et al. Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjögren's syndrome. J Rheumatol 1999;26:1672-5. (Pubitemid 29367303)
12. Miura Y, Yazawa N, Tamaki Z, et al. Anti-p53 antibodies in patients with dermatomyositis/polymyositis. Clin Rheumatol 2007;26:1328-31. (Pubitemid 47034190)
13. Fenton CL, Patel A, Tuttle RM, Francis GL. Autoantibodies to p53 in sera of patients with autoimmune thyroid disease. Ann Clin Lab Sci 2000;30:179-83.
14. Di Cesare E, Previti M, Lombardo F, et al. Serum anti-p53 autoantibodies in patients with type 1 diabetes. Ann Clin Lab Sci 2001;31:253-8. (Pubitemid 32726983)
15. Herkel J, Modrow JP, Bamberger S, et al. Prevalence of autoantibodies to the p53 protein in autoimmune hepatitis. Autoimmunity 2002;35:493-6. (Pubitemid 36321889)
16. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for a diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38. (Pubitemid 29514229)
17. Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histological progression. Hepatology 1999;29:1007-12. (Pubitemid 29168729)
18. Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and responses to therapy. Hepatology 1998;28:296-301. (Pubitemid 28363652)
19. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984;310:899-903. (Pubitemid 14173184)
20. Lubin R, Schlichtholz B, Bengoufa D, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface. Cancer Res 1993;53:5872-6. (Pubitemid 24006152)
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5. (Pubitemid 12218164)
22. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010;139:58-72.
23. Czaja AJ, Morshed SA, Parveen A, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type-1-autoimmune hepatitis. Hepatology 1997;26:567-72. (Pubitemid 27392345)
24. Herkel J, Mimran A, Erez N, et al. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA. J Autoimmun 2001;17:63-9. (Pubitemid 32751882)
25. Himoto T, Murota M, Yoneyama H, et al. Clinical characteristics of patients with autoimmune hepatitis seropositive for anticentromere antibody. Hepatol Res 2010;40:786-92.
26. Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010;55:2144-61.
27. Himoto T, Nakai S, Kinekawa F, et al. Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody. Dig Dis Sci 2009;54:360-8.
28. Czaja AJ, Cassani F, Cataleta M,Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996;24:1068-73. (Pubitemid 26365905)
29. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-64. (Pubitemid 34183971)
30. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984;2:954-6. (Pubitemid 15201176)